Grünenthal acquires cancer treatment Stivarga®

Grünenthal is advancing its strategy of acquiring established medicines with clear medical needs by adding Stivarga (regorafenib), an oral treatment for certain advanced cancers including metastatic disease. The move is intended to leverage Grünenthal's commercial and operational capabilities and support growth, although the article excerpt provides no transaction value or financial terms.